Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amplia Therapeutics ( (AU:ATX) ) has provided an update.
Amplia Therapeutics Limited announced that all resolutions proposed at its Annual General Meeting were successfully passed. The company is advancing its ACCENT trial, which investigates the efficacy of its FAK inhibitor, narmafotinib (AMP945), in combination with other drugs for pancreatic cancer. This development could enhance Amplia’s position in the pharmaceutical industry, particularly in cancer treatment, and potentially benefit stakeholders by advancing treatment options for pancreatic cancer.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is particularly focused on fibrotic cancers such as pancreatic and ovarian cancer, and FAK’s role in chronic diseases like idiopathic pulmonary fibrosis (IPF).
Average Trading Volume: 7,121,802
Technical Sentiment Signal: Buy
Current Market Cap: A$92.43M
See more insights into ATX stock on TipRanks’ Stock Analysis page.